[新聞] 美國撥款3億3千萬給再生元製藥生產etesevimab

看板 Gossiping
作者
時間
留言 11則留言,5人參與討論
推噓 4 ( 4推 0噓 7→ )
備註請放最後面 違者新聞文章刪除 1.媒體來源: 外媒 marketwatch 2.記者署名: By Tomi Kilgore 3.完整新聞標題: Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million 4.完整新聞內文: Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million Published: Sept. 15, 2021 at 6:53 a.m. ET By Tomi Kilgore Eli Lilly & Co. LLY, -2.05% announced Wednesday to sell 388,000 doses of etesevimab, which has been authorized for emergency use as a COVID-19 treatment for $330 million. As part of the deal, about 200,000 doses of etesevimab, which complements doses of bamlanivimab previously purchased by the U.S. government, are expected to ship in the third quarter of 2021, with the remaining doses to be shipped in the fourth quarter. "The recent increase in COVID-19 cases has caused a substantial rise in the utilization of monoclonal antibody drugs, particularly in areas of the country with low vaccination rates," said Lilly's Chief Scientific and Medical Officer Daniel Skovronsky. "Lilly developed bamlanivimab and etesevimab for administration together, in anticipation of variants such as the highly contagious Delta variant, which currently accounts for more than 98 percent of all identified COVID-19 cases in the U.S." Eli Lilly's stock, which was still inactive in premarket trading, has run up 38.1% year to date, while the S&P 500 SPX, -0.57% has gained 18.3%. Eli Lilly & Co. LLY, -2.05% 週三宣布以 3.3 億美元的價格出售 388,000 劑 etesevimab,該藥已被授權緊急用作 COVID-19 治療。作為交易的一部分,約 200,000 劑 etesevimab 補充美國政府先前購買的 bamlanivimab 劑量,預計將於 2021 年第三季 度發貨,其餘劑量將在第四季度發貨。 “最近 COVID-19 病例的增加導致單基因複製抗體藥物的使用大幅增加,特別是在該國 疫苗接種率低的地區,”禮來公司的首席科學和醫學官 Daniel Skovronsky 說。 “禮來開發了 bamlanivimab 和 etesevimab 用於聯合給藥,預防出現變異, 例如高傳染性的 Delta 變異, 斯必克, -0.57% 上漲了 18.3%。 5.完整新聞連結 (或短網址): https://is.gd/XdoJ72 6.備註: 以色列打到第七針後終於看到盡頭了呢!順帶一提Etesevimab的藥源是中國,看來解鈴 還需繫鈴人,藥頭總是最了解自己手上的貨呢! https://imgur.com/jJxylCV Etesevimab(LY-CoV016,又名JS016)最初由君實生物與中國科學院微生物所共同開發, 去年禮來從君實生物獲得授權,主導大中華地區以外全球地區的臨床開發。這兩款抗體均 靶向刺突蛋白受體結合域(RBD),但是靶向RBD的不同表位,因此組合療法可能產生更好 的治療效果。 -- 七魄興輪無上伊甸瑜珈雖然是以看來較為平和的方式以蟬蛻和生乳取代血肉等腥穢之物 作為密義源起供養;然而聚歛於上的是冥界的深冤與大樂奔瀉的淨慈,行者於閉關修持 之時若生起退失動搖之心,則神識旋即離散且肉身消殞;即便如此還是願意受灌頂嗎? https://imgur.com/cEVD0kE ---妖道七祖《攝一切魔根本瑜珈論/誓命問品第一》--- 文章代碼(AID): #1K0Lp7VP (CFantasy) [ptt.cc] Re: [新聞] 湖南偏鄉驚曝百餘...... https://imgur.com/eRQKYMF 文章網址: https://is.gd/J7nd2k --
※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 111.248.99.139 (臺灣) ※ 文章網址: https://www.ptt.cc/bbs/Gossiping/M.1631710850.A.1D9.html
1Fgreensaru: 毒蛇出沒之處,百步之內,必有解蛇毒 223.136.179.69 09/15 21:02
2Fgreensaru: 之物 223.136.179.69 09/15 21:02
3Fbathilda: ?第七針?? 1.200.83.176 09/15 21:06
4FGETpoint: 這款要明年才能到消費者手上 等以色列 111.248.99.139 09/15 21:07
5FGETpoint: 到貨開箱 已經打完七針了吧(目前四針ing 111.248.99.139 09/15 21:08
6Fwhitenoise: 這是治療用藥,參考下面CDC連結 114.39.72.129 09/15 21:09
7Fwhitenoise: https://bit.ly/3zfjNzY 114.39.72.129 09/15 21:09
8Fwhitenoise: 台灣已經有了 114.39.72.129 09/15 21:10
9Fwhitenoise: 禮來是美國的跨國製藥公司 114.39.72.129 09/15 21:12
10Fwaa006: 台灣連中共代理的疫苗都不想進了,這藥也 117.56.69.133 09/15 23:18
11Fwaa006: 不太樂觀了吧 117.56.69.133 09/15 23:18

八卦 看板熱門文章